Skip to content
1st Counsel – Lifestyle
Author:
GOA Therapeutics Corporation
Former Novartis U.S. Chief Strategy Officer Scott Howell, MD, MBA, Joins GOA Therapeutics as Chief Commercial Officer
November 18, 2026
Former Gilead Head of U.S. Medical Affairs Dean Hakanson, MD, Joins GOA Therapeutics as Chief Medical Officer
November 2, 2026
GOA Therapeutics Presents New Data at ANESTHESIOLOGY® 2026 for GOA26, a First-in-Class Candidate for Acute Alcohol Intoxication and Poisoning
October 23, 2026
GOA Therapeutics Launches $300 Million Stock Offerings to Advance First in Class Drug Candidate for Acute Alcohol Intoxication
October 20, 2026
SEC Qualifies GOA Therapeutics’ Public Offering to Sell Up to $300 Million in Stock; Set for Launch October 15
October 13, 2026
GOA Therapeutics Unveils New Data for GOA26, a First-in-Class Drug Candidate for Acute Alcohol Intoxication and Poisoning
October 8, 2026
GOA Therapeutics Files with SEC for Proposed Public Offering, Contemplates Issuing Up to $300 Million in Stock
September 30, 2026
GOA Therapeutics Emerges from Stealth with $15.5 Million in Funding and Unveils GOA26, a First-in-Class Drug Candidate for Acute Alcohol Intoxication and Poisoning
September 17, 2026